CM
FATE icon

Caption Management’s Fate Therapeutics FATE Stock Holding History

Caption Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$734K – 1271
2024
Q1 		$734K Buy
+100,000
New +$619K 0.01% 807
2021
Q4 		– Sell
-30,000
Closed -$1.78M – 1694
2021
Q3 		$1.78M Hold
30,000
– – 0.02% 809
2021
Q2 		$2.6M Buy
+30,000
New +$2.42M 0.03% 585
2021
Q1 		– Sell
-24,400
Closed -$2.22M – 1156
2020
Q4 		$2.22M Buy
24,400
+4,400
+22% +$273K 0.05% 413
2020
Q3 		$800K Buy
+20,000
New +$698K 0.02% 684
2020
Q2 		– Sell
-101,000
Closed -$2.24M – 1016
2020
Q1 		$2.24M Buy
101,000
+1,000
+1% +$25.3K 0.13% 224
2019
Q4 		$1.96M Buy
+100,000
New +$1.59M 0.07% 355

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caption Management's FATE Position: Q2 2025 in Review

Caption Management sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 57,000 shares — an estimated $45K sold.

Caption Management first reported a position in FATE in Q4 2019 and held it in 6 quarters. The position peaked at $1.42M in Q3 2021. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • Caption Management reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 57,000 Fate Therapeutics shares in Q2 2025, an estimated $45K.
  • Caption Management first reported a position in Fate Therapeutics in Q4 2019 and held it in 6 quarters.
  • Caption Management's Fate Therapeutics position peaked at $1.42M in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.